Stimulant
发表于 2025-3-21 16:04:59
书目名称Interventional Therapies for Secondary and Essential Hypertension影响因子(影响力)<br> http://impactfactor.cn/2024/if/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension影响因子(影响力)学科排名<br> http://impactfactor.cn/2024/ifr/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension网络公开度<br> http://impactfactor.cn/2024/at/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension网络公开度学科排名<br> http://impactfactor.cn/2024/atr/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension被引频次<br> http://impactfactor.cn/2024/tc/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension被引频次学科排名<br> http://impactfactor.cn/2024/tcr/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension年度引用<br> http://impactfactor.cn/2024/ii/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension年度引用学科排名<br> http://impactfactor.cn/2024/iir/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension读者反馈<br> http://impactfactor.cn/2024/5y/?ISSN=BK0472988<br><br> <br><br>书目名称Interventional Therapies for Secondary and Essential Hypertension读者反馈学科排名<br> http://impactfactor.cn/2024/5yr/?ISSN=BK0472988<br><br> <br><br>
假装是你
发表于 2025-3-21 21:31:11
http://reply.papertrans.cn/48/4730/472988/472988_2.png
FLAGR
发表于 2025-3-22 03:48:13
Thomas Zeller MD,Ulrich Beschorner MD,Elias Noory MD
导师
发表于 2025-3-22 06:13:11
Maria Boutsikou MD, MSc, PhD,Anselm Uebing MD, PhD,Michael A. Gatzoulis MD, PhD, FACC, FESC
吊胃口
发表于 2025-3-22 11:13:04
http://reply.papertrans.cn/48/4730/472988/472988_5.png
打火石
发表于 2025-3-22 13:07:10
Atul Pathak MD, Phd,Benjamin Honton MD,Mel Lobo MD
吹牛需要艺术
发表于 2025-3-22 18:28:02
http://reply.papertrans.cn/48/4730/472988/472988_7.png
令人不快
发表于 2025-3-22 23:00:07
http://reply.papertrans.cn/48/4730/472988/472988_8.png
Palliation
发表于 2025-3-23 04:35:34
Interventions for Renovascular Hypertensioned trials could prove a benefit of RAS revascularization compared to medical management. These negative trials including the CORAL trial had significant flaws in study design; crucial for a clinical benefit of revascularization of RAS is a proper patient selection, revascularization is only indicate
Acetabulum
发表于 2025-3-23 07:27:30
http://reply.papertrans.cn/48/4730/472988/472988_10.png